Study: Global Drug Makers Move R&D Work To China, India
This article was originally published in PharmAsia News
A new study says Western drug makers are moving an increasing amount of production and clinical trials to China and India. The study conducted by the Ewing Marion Foundation said scientists in the two countries are using research and development activities to create their own intellectual property as part of the globalization of innovation. The study cited Eli Lilly, Johnson & Johnson and Merck as three companies that rely on China and India for advanced R&D work. As of 2006, the study said, 8.4 percent of applications for drug patents listed an inventor in China, 5.5 percent in India. (Click here for more
You may also be interested in...
With clinical failure rates rising industry-wide, a skunkworks at Lilly, called Chorus, has been trying to boost likely-to-succeed shots on goal by getting compounds to human proof-of-concept far faster and cheaper than the internal organization. Lilly's R&D group is skeptical about the program, even anxious -- one reason Chorus has teamed up with a major venture fund to get more molecules to test. If the program works, will Lilly embrace it - or will its venture partner reap the rewards?
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.